Ranbaxy launches acne treatment Absorica
PRINCETON, N.J. — Ranbaxy Labs on Wednesday announced the launch of Absorica (isotretinoin) 25 mg and 35 mg capsules into the U.S. healthcare market.
Absorica has become the most prescribed branded oral isotretinoin in the United States, as per a recent independent survey conducted with dermatologists. The product is licensed by Ranbaxy from Cipher Pharmaceuticals and is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal, however, Absorica, which is formulated using patented Lidose technology, can be given without regards to meals. The fasted AUC0-t of Absorica is approximately 83% greater than that of Accutane, while both products are bioequivalent under federal conditions. Absorica is therefore not interchangeable and not substitutable with generic products of Accutane.
"Since isotretinoin dosing is weight-based, we are most pleased to make available these valuable, additional dosing options exclusively for Absorica," stated Ashish Anvekar, VP Brand Division North America at Ranbaxy. "This will give prescribers the enhanced flexibility to tailor the isotretinoin therapy, depending on the patient's weight, and benefit the group of patients who are in that weight range, irrespective of their dietary intake."
Study: Dietary supplements help lower healthcare costs of coronary heart disease patients
WASHINGTON — Use of specific dietary supplements can have a positive effect on healthcare costs through avoided hospitalizations related to coronary heart disease, according to a new article published Wednesday in the Journal of Dietary Supplements. The article, “From Science to Finance — A Tool for Deriving Economic Implications from the Results of Dietary Supplement Clinical Studies,” written by Christopher Shanahan and Robert de Lorimier, explores a potential cost-benefit analysis tool that, when applied to a high-risk population like U.S. adults over 55 with CHD who take dietary supplements, specifically omega-3 fatty acid or B vitamin dietary supplements, can result in the reduction of the individual's odds of experiencing a costly medical event.
Hospitalizations for all U.S. adults over the age of 55 with CHD cost the United States more than $64 billion in 2012, and the amount spent on the treatment of CHD, rather than the prevention, is burdensome on both the societal and individual levels — and only expected to increase, according to the article. “One way to control the burden of CHD costs is to minimize the number of costly inpatient procedures,” the authors said. “Many dietary supplement products are available in the market today that have been shown to have positive effects on heart health through associated clinical studies. … Thus, the potential decrease of total healthcare expenditures in the United States is a strong argument for the daily use of dietary supplements.”
If every high-risk person in the target population were to take B vitamins at preventive intake levels daily, there would be an average of $1.5 billion in avoided expenditures per year and a cumulative of $12.1 billion in avoided expenditures between 2013 and 2020. “This is a relatively low-technology, yet smart, approach that can be used by consumers, physicians, employers and policymakers as a means to reduce personal and societal healthcare costs,” the authors concluded.
The cost-savings model presented in this article was first presented in a report, “Smart Prevention — Health Care Cost Savings Resulting from the Targeted Use of Dietary Supplements,” in which Frost & Sullivan conducted a systematic review of scientific research in peer-reviewed, published studies that looked separately at relationships between omega-3 supplement intake and the risk of a CHD-attributed event, and B vitamins intake and the risk of a CHD-attributed event. The firm then projected the rates of CHD-attributed medical events across U.S. men and women over the age of 55 with CHD and applied a cost-benefit analysis to determine the cost savings if people in this targeted population took omega-3 supplements or B vitamin supplements at preventive intake levels. That report was funded through a grant from the CRN Foundation.
Rite Aid kicks off Vote for Your Favorite Pharmacy Team Member Contest with new video voting feature
CAMP HILL, Pa. — To kick off American Pharmacists Month, Rite Aid is bringing back its nationwide Vote for Your Favorite Pharmacy Team Member Contest with a new video voting feature. Through the contest, Rite Aid customers have a chance to win $2,500 in Rite Aid gift cards by nominating a favorite member of their Rite Aid pharmacy team. The contest, now in its eleventh year, was designed to recognize Rite Aid pharmacy associates including pharmacists, pharmacy technicians, pharmacy cashiers and Wellness Ambassadors, for their commitment to providing excellent customer service.
"American Pharmacist Month is the perfect time to honor the Rite Aid pharmacy teams for their year-round commitment to providing excellent patient care," stated Dan Miller, Rite Aid SVP pharmacy operations. "Every day, they are making a difference in the lives of their customers and the communities we serve. This program is just one small way we can thank them for their hard work and dedication towards improving the health and wellbeing of our customers."
From now through Oct. 31, in addition to uploading a video nomination at RiteAid.com/vote, customers can vote for their favorite pharmacy team member by completing a mail-in nomination form available at any Rite Aid pharmacy or online at RiteAid.com/vote. Customers who vote will automatically be entered into a random drawing to win $2,500 in Rite Aid gift cards. One nominated pharmacy team member also will win $2,500 in Rite Aid gift cards through a random drawing.
All "favorite" Rite Aid pharmacy team members will be recognized by Rite Aid with a Favorite Pharmacy Team Member lapel pin and a letter of commendation from Rite Aid's chairman and CEO John Standley.
Loading Post Please Wait...